Should a Patient With Primary Intracerebral Haemorrhage Receive Antiplatelet or Anticoagulant Therapy?
BMJ 331:439-442, Wani,M.,et al, 2005
Summary of Evidence-Based Guideline: Complementary and Alternative Medicine in Multiple Sclerosis
Neurol 82:1083-1092, Yadav, V.,et al, 2014
Guidelines for the Prevention of Stroke in Patients With Stroke or Transient Ischemic Attack: A Guideline for Healthcare Professionals From the American Heart Association/American Stroke Association
Stroke 42:227-276, Furie,K.L.,et al, 2011
Diagnosis and Management of Cerebral Venous Thrombosis: A Statement for Healthcare Professionals From the American Heart Association/American Stroke Association
Stroke 42:1158-1192, Saposnik,G.,et al, 2011
Multiple Sclerosis Therapeutics: Unexpected Outcomes Clouding Undisputed Successes
Neurol 72:1008-1015, Wiendl,H. &Hohlfeld,R., 2009
Assessment: The Use of Natalizumab (Tysabri) for the Treatment of Multiple Sclerosis (An Evidence-Based Review): Report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology
Neurol 71:766-773, Goodin,D.S.,et al., 2008
Practice Parameter: The Diagnostic Evaluation and Treatment of Trigeminal Neuralgia (An Evidence-Based Review): Report of the Quality Standards Subcommittee of the AAN & EFNS
Neurol 71:1183-1190, Gronseth,G.,et al, 2008
Intravenous Immunoglobulin in Autoimmune Neuromuscular Diseases
JAMA 291:2367-2375, Dalakas,M.C., 2004
Practice Parameter: Evidence-Based Guidelines for Migraine Headache (an Evidence-Based Review)
Neurol 55:754-763, Silberstein,S.D. et al, 2000